MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen next
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 2026-06-28
- Source
- OpenAlex
- PubMed
- Unavailable
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal IdeationThe Journal of Clinical Psychiatry · 2026-05-11Acute Effects of 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) Compared With Psilocybin and MDMA in Healthy ParticipantsBiological Psychiatry · 2026-04-24Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical ImplicationsFOCUS The Journal of Lifelong Learning in Psychiatry · 2026-03-31Psychedelics in NHS services: exploring a model for real-world implementation of psilocybinThe British Journal of Psychiatry · 2026-03-29Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case reportBMC Psychiatry · 2025-02-27Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticityTranslational Psychiatry · 2026-06-04Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of CareCurrent Psychiatry Reports · 2026-05-13Prevalence and Correlates of Past-Year Psilocybin Use in the United StatesAmerican Journal of Psychiatry · 2026-04-21